Low temperature preparation of diopside nanoparticles: in-vitro bioactivity and drug loading evaluation

Abstract

Bioactive diopside (CaMgSi₂O₆) nanoparticles have recently gained potential usefulness as bone replacement materials and nano vehicles for delivering therapeutics. The structural characteristics of this ceramic have found to be a key factor in bone bonding ability. To attain the desired product for 100% clinical success, it is important to realize the relationship between structure and biological activity. Synthesis of these nanoparticles via the solid-state method has been regarded as a low-cost and easy process in large-scale, but time consuming reactions and high temperature (≈ 1400 °C) are required. On the other side, the wet chemistry can overcome these drawbacks, whereas the presence of byproducts in the final powder has limited this method in large-scale production. The present document has represented a simple, fast and one-pot sol-gel approach for the synthesis of highly pure diopside nano-powders (< 20 nm) by using not-expensive precursors. Calcination of the obtained powder has been conducted at various temperatures (700, 1000 and 1200 °C). The physicochemical and microstructural properties of the products have been characterized by XRD, FTIR, FESEM and TEM. Moreover, the impact of the crystallinity on the bioactivity, drug loading capacity and drug release behavior of the synthesized nanoparticles have been investigated here for the first time. The in-vitro bioactivity results of the prepared diopside samples in a simulated body fluid (SBF) at 37 °C revealed the higher capability of the sintered sample to deposit calcium phosphate, compared with the amorphous one. High quantity of gentamicin (around 10 µg) could attach to the surface of 1 miligram of the sintered diopside during the early stages of contact (3 h), suggesting the potential use of diopside as a new class of nano-vehicles for antibiotics. The release behavior indicated a sustained release of gentamicin (80%) after 24 h. In conclusion, diopside nanoparticles can be a promising candidate as a drug-vehicle for bone filling, implant coating or bone cement applications.